Could You Have Seen The Run In Guardant Health Stock Coming?
For questions about this article or underlying research, email help@trefis.com.
Guardant Health (GH) stock gained 60.6% in the twelve months to November 10, 2026, on top of a 131.8% rise in the six months before that. By the end of that run, Shield, the company’s blood test for colorectal cancer screening, was its fastest-growing business. Spotting it early meant seeing Shield’s progress, and the rest of the business starting to pay its way, before November 2025. So what was Guardant saying about Shield back then?
What Guardant Said About Shield By June 2025
Guardant said it plainly on its February 2025 earnings call: Shield had received FDA approval, in July 2024, and Medicare coverage. That put the test’s progress on the record, in management’s own words, more than eight months before November 2025. In June 2025, the National Comprehensive Cancer Network added Shield to its colorectal cancer screening guidelines.
Shield remained a promise rather than a result, however. During that same February call, management said 2024 growth in its cancer-test volume came largely from its Guardant360 tests, and Shield had just finished its first full quarter on sale.
By October 2025, Guardant’s Revenue Growth Had Sped Up
Guardant’s overall numbers improved during 2025. Revenue rose 20.8% from a year earlier in the quarter ended March 2025, then 30.9% in the quarter ended June. On September 4, Guardant said an updated version of Shield’s screening algorithm had met all the primary goals of its clinical study.
Revenue growth in the September quarter, reported on October 29, 2025, reached 38.5%. Over those same quarters, the operating loss shrank to 37.3% of revenue from 54.6%.
On the October 29 call, management also pointed to “the rest of the business becoming cash flow positive one quarter earlier than expected.” Before November 2025, both the filings and management were saying Guardant was moving toward paying its way.
Which Guardant Business Had Grown Fastest By 2026?
Screening, which is Shield, grew the fastest. In the quarter ended September 2026, screening revenue reached $68 million, up from $24 million a year earlier. That accounted for nearly a fifth of Guardant’s $361 million in revenue for the quarter. Over the twelve months of Guardant’s run, the S&P 500 returned 13.1%. Peer Natera rose 56.3% over the same dates, while Tempus AI gained 12.5%. Guardant’s 60.6% was only a little ahead of Natera’s.
Oncology is still the larger business: it brought in $231 million in the quarter, up 25%. Shield also has further to go on cash. Management expects screening, as a stand-alone business, to reach cash flow breakeven by the end of 2028.
Is Guardant Still Showing The Same Signs Today?
On Shield, yes. In the quarter ended September 2026, Shield volume grew 246% to 83,000 tests. UnitedHealthcare coverage took effect in August, and management estimates that about 100 million people will be covered for Shield as 2027 begins.
The money side has moved less. Guardant’s operating loss was 36.8% of revenue in the September 2026 quarter, little changed from the September 2025 quarter. Management also raised its 2026 free cash flow burn forecast to $205 million to $220 million, from $195 million to $205 million, citing a delay by CMS in processing claims for a new test. Management called the delay temporary and said those payments will shift to the first half of 2027. Outside screening, management expects the business to produce positive free cash flow for all of 2026, and it still targets breakeven for the whole company by the end of 2027.
Shield adoption is still building, while Guardant’s operating loss, measured against revenue, has barely narrowed from a year earlier. Its operating loss as a share of revenue is the number to watch in the report expected in February 2027.
What Would Selling Guardant Health Cost You In Tax?
If your shares have gained a lot, selling can bring a big tax bill, and holding keeps the risk. A free 30-minute strategy review with our partner advisory firm covers protecting the gain and a lower-tax way to trim.
Spot an error or want more like this? Tell us in 10 seconds.